Valor begins dosing in Phase I trial of IGN002 to treat non-Hodgkin lymphoma

Valor Biotherapeutics (Valor) has started a Phase I clinical trial of its lead product candidate, IGN002, to treat patients with refractory and relapsed non-Hodgkin lymphoma (NHL).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news